Craig Coleman
Professor/Pharmacy Practice

Are you Craig Coleman?

How to update your information.
Murad MH,... Coleman C, et al. Improving the utility of evidence synthesis for decision makers in the face of insufficient evidence. J Clin Epidemiol. 2021 Jul;135:170-175. doi: 10.1016/j.jclinepi.2021.02.028. Epub 2021 Mar 19. PMID: 33753229.
2021
Research Type: Journal Article

Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
2021
Thomas Bunz, J Beyer-Westendorf, Craig Coleman, K T Moore, V Ashton, D Milentijevic, O S Costa
Research Type: Journal Article

Improving the utility of evidence synthesis for decision makers in the face of insufficient evidence
2021
Andrew R. Zullo, Jennifer S. Lin, Craig Coleman, Carolyn M. Rutter, Elizabeth Stoeger, Shazia Siddique, Brian Leas, Ethan M. Balk, Stephanie M. Chang, Timothy J. Wilt, Karen Robinson, Olivia Costa, Mark Helfand, Meera Viswanathan, Amy Y. Tsou, Celia V. Fiordalisi, M. Hassan Murad
Research Type: Journal Article

Welcome to the cardiovascular outcomes trials issue
2021
Olivia S. Costa, Craig Coleman
Research Type: Other Scholarly Work

Improving the Utility of Evidence Synthesis for Decision Makers in the Face of Insufficient Evidence [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Apr. Report No.: 21-EHC007. PMID: 33905185.
2021
Research Type: Other Scholarly Work

Ophthalmic Complications in Patients with Nonvalvular Atrial Fibrillation and Type 2 Diabetes Prescribed Rivaroxaban or Warfarin
2021
Research Type: Poster/Presentation

Stroke, Systemic Embolism, Vascular Death and Bleeding in Nonvalvular Atrial Fibrillation Patients with Type 2 Diabetes Receiving Rivaroxaban or Warfarin
2021
Research Type: Poster/Presentation

Ophthalmic complications in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin.
2021
Research Type: Poster/Presentation

Thromboembolism, bleeding, and vascular death among older and younger nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
2021
Research Type: Poster/Presentation

Characterizing safety and efficacy in ovarian cancer patients with thromboembolism treated with rivaroxaban.
2021
Research Type: Poster/Presentation

Interview with the expert: RIVA-DM – What do recent data tell us?
2021
Research Type: Poster/Presentation

Kidney, limb and ophthalmic complications and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: An electronic health record analysis.
2021
Research Type: Poster/Presentation

Patient characteristics and temporal changes in anticoagulation treatment patterns in patients diagnosed with cancer-associated thrombosis: An oscar-us analysis.
2021
Research Type: Poster/Presentation

Kidney, Limb and Ophthalmic Complications and Death in Patients with Nonvalvular Atrial Fibrillation Prescribed Rivaroxaban or Warfarin: An Electronic Health Record Analysis
2021
Research Type: Poster/Presentation

Do differences in baseline clinical severity of ovarian cancer patients with thrombosis predict treatment with rivaroxaban versus low molecular-weight heparin?.
2021
Research Type: Poster/Presentation

Adherence and persistence to rivaroxaban in non-valvular atrial fibrillation patients receiving 30- or 90-day supply prescription fills.
2022
Craig Coleman, Thomas Bunz, V Ashton
Research Type: Journal Article

Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study.
2022
B Schaefer, Craig Coleman, B Vardar, F Kleinjung, T Vaitsiakhovich
Research Type: Journal Article

Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
2022
Craig Coleman, William L Baker Jr., A A Kharat, B Bookhart
Research Type: Journal Article

A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years.
2022
C W Brescia, O S Costa, B Vardar, N Sood, Craig Coleman, L Hofmeister, K Abdelgawwad
Research Type: Journal Article

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
2022
B Lovelace, Craig Coleman, M Sharma, J Beyer-Westendorf, O S Costa, M J Christoph, S J Connolly
Research Type: Journal Article